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WASs have yielded large lists of disease-associated loci. Progress in identifying the causal variants driving these associations, particularly for complex psychiatric disorders such as schizophrenia, has lagged much further behind. Interpreting associated variants and loci is therefore vital to understanding how genetic variation contributes to disease pathology. Expression quantitative trait loci (eQTLs), which are responsible for a substantial proportion of gene expression variance, have been posited as a link between associated loci and disease susceptibility [1] [2] [3] [4] [5] , and have yielded results for a host of complex traits [6] [7] [8] [9] . Consequently, numerous methods to identify and interpret colocalization of eQTLs and GWAS loci have been developed [10] [11] [12] [13] . However, these methods require simplifying assumptions about genetic architecture (that is, one causal variant per GWAS locus) and/or linkage disequilibrium; may be underpowered or overly conservative, especially in the presence of allelic heterogeneity; and have not yet yielded substantial insights into disease biology.
Biologically relevant transcriptomic information can be extracted through detailed RNA-sequencing (RNA-seq), as recently described by the CommonMind Consortium 14 (CMC) in a large cohort of genotyped individuals with schizophrenia and bipolar disorder 14 . These analyses, however, are underpowered to detect statistically significant differential expression of genes mapping at schizophrenia (SCZ) risk loci, due to the small effects predicted by GWAS, combined with the difficulty of obtaining adequate sample sizes of neurological tissues 14 , and do not necessarily identify all risk variation in GWAS loci. Transcriptomic imputation is an alternative approach that leverages large eQTL reference panels to bridge the gap between large-scale genotyping studies and biologically useful transcriptome studies 15, 16 . Transcriptomic imputation approaches codify the relationships between genotype and gene expression in matched panels of individuals, then impute the genetic component of the transcriptome into large-scale genotype-only datasets, such as case-control GWAS cohorts, enabling investigation of disease-associated gene expression changes. This will allow us to study genes with modest effect sizes, likely representing a large proportion of genomic risk for psychiatric disorders 14, 17 . The large collection of DLPFC gene expression data collected by the CMC 14 affords us a unique opportunity to study and codify relationships between genotype and gene expression. Here, we present a novel set of gene expression predictor models, built using CMC DLPFC data 14 . We compare different regression approaches to building these models (including elastic net 15 , Bayesian sparse linear mixed models and ridge regression 16 , and using max eQTLs), and benchmark performance of these predictors against existing GTEx prediction models. We applied our CMC DLPFC predictors and 12 GTEx-derived neurological prediction models to predict gene expression in SCZ GWAS data, obtained through collaboration with the Psychiatric Genomics Consortium (PGC) SCZ working group, the 'CLOZUK2' cohort, and the iPSYCH-GEMS SCZ working group. We identified 413 genome-wide significant genic associations with SCZ in our PGC + CLOZUK2 sample, constituting 67 independent associations outside the MHC region. We demonstrated the relevance of these associations to SCZ etiopathology by using gene set enrichment analysis, and by examining the effects of manipulation of these genes in mouse models. Finally, we investigated the spatiotemporal expression of these genes by using a developmental transcriptome dataset, and identified distinct spatiotemporal patterns of expression across our associated genes.
Results
Prediction models based on CMC DLPFC expression. Using matched CMC genotype and gene expression data, we developed DLPFC genetically regulated gene expression (GREX) predictor models. We systematically compared four approaches to building predictors 15, 16 within a cross-validation framework. Elastic net regression had a higher distribution of cross-validation R 2 (R CV 2 ) and higher mean R CV 2 values (Supplementary Figs. 1 and 2a) than all other methods. We therefore used elastic net regression to build our prediction models. We compared prediction models created using elastic net regression on SVA-corrected and uncorrected data 14 . The distribution of R cv 2 values for the SVA-based models was significantly higher than that for the uncorrected data 14, 18 (KS test; P < 2.2 × 10 −16
; Supplementary Fig. 1b,c) . In total, 10,929 genes were predicted with elastic net cross-validation R cv 2 > 0.01 in the SVAcorrected data and were included in the final predictor database (mean R cv 2 = 0.076). To test the predictive accuracy of the CMC-derived DLPFC models, and to benchmark this against existing GTEx-derived prediction models, GREX was calculated in an independent DLPFC RNA-seq dataset (the Religious Orders Study Memory and Ageing Project, ROSMAP 19, 20 ). We compared predicted GREX to measured ROSMAP gene expression for each gene (Replication R 2 , or R R 2 ) for the CMC-derived DLPFC models and 12 GTEx-derived brain tissue models 15, 21 ( Fig. 1 and Supplementary Fig. 2b ). CMC-derived DLPFC models had higher average R R 2 values (mean R R 2 = 0.056), more genes with R R 2 > 0.01, and significantly higher overall distributions of R R 2 values than any of the 12 GTEx models (KS test, P < 2.2 × 10 −16 across all analyses; Fig. 1 ). Median R R 2 values were significantly correlated with sample size of the original tissue set (ρ = 0.92, P = 7.2 × 10 −6 ), the number of genes in the prediction model (ρ = 0.9, P = 2.6 × 10 ), and the number of significant 'eGenes' in each tissue type (ρ = 0.95, P = 5.5 × 10 −7
; Fig. 1c) . Notably, these correlations persist after removing obvious outliers (Fig. 1c) .
To estimate transancestral prediction accuracy, GREX was calculated for 162 African American individuals and 280 European individuals from the NIMH Human Brain Collection Core (HBCC) dataset ( Supplementary Fig. 2c ). R R 2 values were higher on average in Europeans than in African Americans (average R R_EUR 2 = 0.048, R R_AA 2 = 0.040), but were significantly correlated between African
Americans and Europeans (ρ = 0.78, P < 2.2 × 10
, Pearson test; Supplementary Fig. 3 ).
Application of transcriptomic imputation to schizophrenia. We used CMC DLPFC and 12 GTEx-derived brain tissue prediction models to impute GREX of 19,661 unique genes in cases and controls from the PGC-SCZ GWAS study 22 . Predicted expression levels were tested for association with SCZ. Additionally, we applied CMC and GTEx-derived prediction models to summary statistics from 11 PGC cohorts (for which raw genotypes were unavailable) and the CLOZUK2 cohort. Meta-analysis was carried out across all PGC-SCZ and CLOZUK2 cohorts by using an inverse-variance-based approach in METAL. Our final analysis included 40,299 cases and 65,264 controls ( Supplementary Fig. 4a ).
We identified 413 genome-wide significant associations, representing 256 genes in 13 tissues (Fig. 2a) . The largest number of associations was detected in the CMC-DLPFC GREX data ( Fig. 2c; 49 genes outside the MHC, 69 genes overall). We sought replication of our CMC DLPFC SCZ associations in an independent dataset of 4,133 cases and 24,788 controls in collaboration with the iPSYCH-GEMS SCZ working group ( Supplementary Fig. 4b ). We tested for replication of all Bonferroni-significant genes identified in our CMC-DLPFC analysis. Twelve out of 100 genes replicated in the iPSYCH-GEMS data, significantly more than expected by chance (binomial test, P = 0.0043). Notably, 11 of 12 replicating loci are previous GWAS loci, compared with 38 of 88 nonreplicating loci. There was significant concordance between our discovery (PGC + CLOZUK2) and replication (iPSYCH-GEMS) samples; 72 of 100 genes have consistent direction of effect, including all 12 replicating genes (binomial P = 1.258 × 10 ), and we found significant correlation of effect sizes (P = 1.784 × 10 ; ρ= 0.036) and -log 10 P values (P = 1.073 × 10 ; ρ = 0.043). To identify the top independent associations within genomic regions, which include multiple associations for a single gene across tissues or multiple nearby genes, we partitioned genic associations into 58 groups defined based on genomic proximity and applied stepwise forward conditional analysis within each group (Supplementary Table 1 ). In total, 67 non-MHC genes remained genome-wide significant after conditioning (Table 1 and Fig. 2a,b) . The largest signal was identified in the CMC-DLPFC GREX data (24 genes; Fig. 2c ), followed by the putamen (seven genes). 19 out of 67 genes did not lie within 1 Mb of a previously genome-wide significant GWAS locus 22 (shown in bold in Table 1 ); of these, 5 of 19 genes were within 1 Mb of a locus that approached genome-wide significance (P < 5 × 10
−07
). The remaining 14 genes all fall within nominally significant PGC-SCZ GWAS loci (P < 8 × 10
), but did not reach genome-wide significance.
We compared our CMC-DLPFC prediXcan associations statistics to COLOC results from our recent study 10, 23 . Briefly, COLOC tests for colocalization between GWAS loci and eQTL architecture. We calculated COLOC probabilities of no colocalization ('PP3') and colocalization ('PP4'); we consider PP4 > 0.5 to be significant evidence of colocalization 24 . We found a significant correlation between prediXcan P values and PP4 values; ρ = 0.35, P = 2.3 × 10 −311
. Thirtyone genes had 'strong' evidence of colocalization between GWAS loci and lead or conditional eQTLs 23 ; of these, 21 were genomewide significant in our prediXcan analysis (significantly more than expected by chance, binomial P value = 2.11 × 10 −104 ), and all had P < 1 × 10 −4 . We identified 40 GWAS loci with no significant prediXcan associations; all of these loci also had strong evidence for no colocalization in our COLOC analysis (median PP3 = 0.936, median PP4 = 0.0027).
Implicated genes highlight SCZ-associated molecular pathways.
We tested for overlap between our non-MHC SCZ-associated genes and 8,657 gene sets comprising (1) hypothesis-driven pathways and (2) general molecular database pathways. We corrected for multiple testing by using the Benjamini-Hochberg false discovery rate (FDR) correction 25 . We identified three significantly associated pathways in our hypothesis-driven analysis ( Table 2) . Targets of the fragile-X mental retardation protein formed the most enriched pathway (FMRP; P = 1.96 × 10
−8
). Loss of FMRP inhibits synaptic function, is comorbid with autism spectrum disorder, and causes intellectual disability as well as psychiatric symptoms including anxiety, hyperactivity, and social deficits 26 . Enrichment of this large group of genes has been observed frequently in studies of SCZ 27, 28 and autism 26, 29 . There was a significant enrichment among our SCZ-associated genes and genes that have been shown to be intolerant to loss-of-function mutations 30 (P = 5.86 × 10
) and with copy number variants (CNVs) associated with bipolar disorder 31 (P = 7.92 × 10
), in line with a recent GWAS study of the same individuals 28 .
Next, we performed an agnostic search for overlap between our SCZ-associated genes and ~8,500 molecular pathways collated from large, publicly available databases. Thirty-three pathways were significantly enriched after FDR correction (Table 2  and Supplementary Table 2) , including a number of pathways with some prior literature in psychiatric disease. We identified an enrichment with porphyrin metabolism (P = 1.03 × 10 −4 ). Deficiencies in porphyrin metabolism lead to 'porphyria' , an adult-onset metabolic disorder with a host of associated psychiatric symptoms, in particular, episodes of violence and psychosis [32] [33] [34] [35] [36] [37] . Five pathways potentially related to porphyrin metabolism, regarding abnormal iron level in the spleen, liver, and kidney, are also significantly enriched, including two or five of the most highly enriched pathways (P < 2.0 × 10 −4 ). The PANTHER and REACTOME pathways for heme biosynthesis and the GO pathway for protoporphyrinogen IX metabolic process, which are implicated in the development ) in our results. This enrichment is not driven by a single highly associated gene, but rather, every single gene in the HEX-A pathway is nominally significant in the SCZ association analysis (Supplementary Table 2 ). Deficiency of hexosaminidase A (HEX-A) results in serious neurological and mental problems, most commonly presenting in infants as Tay-Sachs disease 38 . Adult-onset HEX-A deficiency presents with neurological and psychiatric symptoms, notably including onset of psychosis and SCZ 39 . Five pathways corresponding to Ras and Rab signaling, protein regulation, and GTPase activity were enriched (P < 6 × 10
−5
). These pathways have a crucial role in neuron cell differentiation 40 and migration 41 , and have been implicated in the development of SCZ and autism [42] [43] [44] [45] . We also find significant enrichment with protein phosphatase type 2A regulator activity (P = 5.24 × 10 −5
), which was associated with major depressive disorder (MDD) and across MDD, bipolar disorder (BPD) and SCZ in the same large integrative analysis 46 , and has been implicated in antidepressant response and serotonergic neurotransmission 47 .
GREX associations are consistent with functional validation. To test the functional impact of our SCZ-associated predicted gene expression changes (GREX), we performed two in silico analyses. First, we compared differentially expressed genes in the Fromer et al. CMC analysis 27 to DLPFC prediXcan results. Out of 460, 76 were nominally significant in the DLPFC prediXcan analysis, significantly more than would be expected by chance (binomial test,
). In particular, the Fromer et al. analysis highlighted six loci where expression levels of a single gene putatively affected SCZ risk. All six of these genes are nominally significant in our DLPFC analysis, and two (CLCN3 and FURIN) reach genome-wide significance. In the conditional analysis across all brain regions, one additional gene (SNX19) reaches genome-wide significance. The direction of effect for all six genes matches the direction of gene expression changes observed in the original CMC paper, indicating that gene expression estimated in the imputed transcriptome reflects measured expression levels in brains of individuals with SCZ. Further, this observation is consistent with a model where the differential expression signature observed in CMC is caused by genetics rather than environment.
To understand the impact of altered expression of our 67 SCZassociated genes, we performed an in silico analysis of mouse mutants by collating large, publicly available mouse databases [48] [49] [50] [51] . We identified mutant mouse lines lacking expression of 37 out of 67 of our SCZ-associated genes, and obtained 5,333 phenotypic data points relating to these lines, including 1,170 related to behavioral, neurological, or craniofacial phenotypes. Out of 37 genes, 25 were associated with at least one behavioral, neurological, or related phenotype (Supplementary Table 3) .
We carried out two tests to assess the rate of phenotypic abnormalities in SCZ-associated mouse lines. First, we compared the proportion of SCZ-gene lines with phenotypic abnormalities to the 'baseline' proportion across all mouse lines for which we had available data. SCZ-associated lines were significantly more likely to display any phenotype (paired t test, P = 0.009647). Next, we Sixty-seven non-MHC genes are significantly associated with SCZ following conditional analysis. Effect sizes (BETA) refer to predicted GREX in cases compared with controls. Effect sizes and odds ratios are also shown adjusted to 'unit' variance in gene expression. OR, odds ratio; DLPFC, dorso-lateral prefrontal cortex; GVAR, genetic variance. Distinct pattern of SCZ risk throughout development. We assessed expression of our SCZ-associated genes throughout development using BrainSpan 52 . Data were partitioned into eight developmental stages (four prenatal, four postnatal), and four brain regions 31, 52 ( Fig. 3a) . SCZ-associated genes were significantly coexpressed in both prenatal and postnatal development and in all four brain regions, based on local connectedness 53 ( Fig. 3b) , global connectedness 53 (that is, average path length between genes; Supplementary Fig. 5 ), and network density (that is, number of edges; Supplementary Fig. 6 ). Examining pairwise gene expression correlation ( Supplementary Fig. 7 ) and gene coexpression networks ( Supplementary Fig. 8 ) for each spatiotemporal point indicated that the same genes do not drive this coexpression pattern throughout development, but rather, it appears that separate groups of genes drive early prenatal, late prenatal, and postnatal clustering.
To visualize this, we calculated z scores measuring the spatiotemporal specificity of gene expression for each SCZ-associated gene, across all 32 time points (Fig. 4) . Genes clustered into four groups ( Supplementary Fig. 9 ) with distinct spatiotemporal expression signatures. The largest cluster (cluster A, Fig. 4a, 29 genes) spanned early to late mid-prenatal development (4-24 weeks post conception (p.c.w.)), either across the whole brain (22 genes) or in regions 1-3 only (seven genes). Twelve genes were expressed in late prenatal development ( Fig. 4d; 25-38 p.c.w.), ten genes were expressed in regions 1-3, postnatally and in the late prenatal period We tested for enrichment of 8,657 pathways among our prediXcan results, using a competitive P value in MAGMA and calculated an FDR-corrected P value to determine significance. FMRP, fragile-X mental retardation protein; BP, bipolar; CNV, copy number variant; LOF, loss of function.
( Fig. 4c) , and 15 genes were expressed throughout development (Fig. 4b) , either specifically in region 4 (nine genes) or throughout the brain (six genes). In order to probe the biological relevance of our four BrainSpan clusters, we compared these gene lists to known and candidate gene sets with relevance to SCZ 54 . Genes in clusters A and B (clusters with prenatal expression) were involved in brain morphology and development, nervous system development, neuron development and morphology, and synaptic development, function, and morphology (Supplementary Table 4 ). These associations were not seen in clusters C and D (genes with late prenatal and postnatal expression).
We noticed a relationship between patterns of gene expression and the likelihood of behavioral, neurological, or related phenotypes in our mutant mouse model database. Mutant mice lacking genes expressed exclusively prenatally in humans, or genes expressed pre-and postnatally, were more likely to have any behavioral or neurological phenotypes than mutant mice lacking expression of genes expressed primarily in the third trimester or postnatally (P = 1.7 × 10 −4 ) ( Supplementary Fig. 10 ).
Discussion
In this study, we present DLPFC gene expression prediction models, constructed using CommonMind Consortium genotype and gene expression data. These prediction models may be applied to either raw data or summary statistics, in order to yield tissue-specific gene expression information in large data sets. This allows researchers to access transcriptome data for non-peripheral tissues at scales currently prohibited by the high cost of RNA-seq and circumvents distortions in measures of gene expression stemming from errors of measurement or CB. b, Average clustering coefficients were calculated for all pairs of SCZ-associated genes, and compared with average clustering coefficients for 100,000 permuted gene networks to obtain empirical significance levels.
environmental influences. As disease status may alter gene expression but not the germline profile, analyzing genetically regulated expression ensures that we identify only the causal direction of effect between gene expression and disease 15 . Large, imputed transcriptomic datasets represent the first opportunity to study the role of subtle gene expression changes (and therefore modest effect sizes) in disease development.
There are some inherent limitations to this approach. The accuracy of transcriptomic imputation is reliant on access to large eQTL reference panels, and it is therefore vital that efforts to collect and analyze these samples continue. Transcriptomic imputation has exciting advantages for gene discovery as well as downstream applications 15, 55, 56 ; however, the relative merits of existing methodologies are as yet underexplored. Here, sparser elastic net models better captured gene expression regulation than BSLMM; at the same time, the improved performance of elastic net over max-eQTL models suggests that a single eQTL model is oversimplified 2, 15 . Fundamentally, transcriptomic imputation methods model only the genetically regulated portion of gene expression and thus cannot capture or interpret variance of expression induced by environment or lifestyle factors, which may be of particular importance in psychiatric disorders. Given the right study design, analyzing genetic components of expression together with observed expression could open doors to better study the role of gene expression in disease.
Sample size and tissue matching contribute to accuracy of transcriptomic imputation results. Our CMC-derived DLPFC prediction models had higher average validation R 2 values in external DLPFC data than GTEx-derived brain tissue models. Notably, the model with the second highest percent of genes passing the R 2 threshold is the thyroid, which has the largest sample size among the GTEx brain prediction models. When looking at mean R 2 values, the second highest value comes from the GTEx frontal cortex, despite the associated small sample size, implying at least some degree of tissue specificity of eQTL architecture.
We compared transcriptomic imputation accuracy in European and African American individuals and found that our models were applicable to either ancestry with only a small decrease in accuracy. Common SNPs shared across ancestries have important effects on gene expression, and as such, we expect GREX to have consistency across populations. There is a well-documented dearth of exploration of genetic associations in non-European cohorts 57, 58 . We believe that these analyses should be carried out in non-European cohorts.
We applied the CMC DLPFC and GTEx-derived prediction models to SCZ cases and controls from the PGC2 and CLOZUK2 collections, constituting a large transcriptomic analysis of schizophrenia. Predicted gene expression levels were calculated for 19,661 unique genes across brain regions (Fig. 1c) and tested for association with SCZ case-control status. We identified 413 significant associations, constituting 67 independent associations. We found significant replication of our CMC DLPFC associations in a large independent replication cohort, in collaboration with the iPSYCH-GEMS consortium. Our prediXcan results were significantly correlated with colocalization estimates ('PP4') from COLOC. Importantly, GWAS loci with no significant prediXcan associations also had no evidence for colocalization with eQTLs. Together, these results imply that our prediXcan associations identify genes with good evidence for colocalization between GWAS and eQTL architecture, and are not contaminated by linkage disequilibrium. One caveat is that four of our associations (SNX19, NAGA, TYW5, and GNL3) have no evidence for colocalization in COLOC results, or after visual inspection of local GWAS and eQTL architecture, and may be false positives.
We compared our CMC DLPFC associations to results using a single-eQTL-based method, SMR 12 , in the PGC+CLOZUK SCZ GWAS 59 , which identified 12 genome-wide significant associations. All significant SMR associations were also significant in our DLPFC prediXcan analysis, and all directions of effect were concordant between the two studies. A recent TWAS study of 30 GWAS summary statistic traits 55 identified 38 non-MHC genes associated at tissue-level significance with SCZ in CMC-and GTEx-derived brain tissues (that is, matching those used in our study). Of these, 26 also reach genome-wide significance in our study, although in many instances these genes are not identified as the lead independent associated gene following our conditional analysis. Among our 67 SCZ-associated genes, 19 were novel, that is, did not fall within 1 Mb of a previous GWAS locus (including five of seven novel brain genes identified in the recent TWAS analysis).
We used conditional analyses to identify independent associations within loci. These analyses clarify the most strongly associated genes and tissues (Table 1) , though we note that nearly colinear gene-tissue pairs could also represent causal associations. The tissues highlighted allowed us to tabulate apparently independent contributions to SCZ risk from different brain regions, even though their transcriptomes are highly correlated generally. We find DLPFC and cerebellum effects, as well as from putamen, caudate, and nucleus accumbens basal ganglia. One caveat here is that tissue associations are likely driven by sample size of the eQTL reference panel, as well as biology. It is likely that the large sample size of the DLPFC reference panel contributes partially to the greater signal identified in the DLPFC.
We used these genic associations to search for enrichments with molecular pathways and gene sets and identified 36 significantly enriched pathways. Among novel pathways, we identified a significant association with HEX-A deficiency. Despite the well-studied and documented symptomatic overlap between adult-onset HEX-A deficiency and SCZ, we believe that this is the first demonstration of shared genetics between the disorders. Notably, this overlap is not driven by a single highly associated gene that is shared by both disorders, but rather, every single gene in the HEX-A pathway is nominally significant in the SCZ association analysis, and five genes have P < 1 × 10 −3 , indicating that there may be substantial shared genetic etiology between the two disorders that warrants further investigation. Additionally, we identified a significant overlap between our SCZ-associated genes and a number of pathways associated with porphyrin metabolism. Porphyric disorders have been well characterized and are among early descriptions of 'schizophrenic' and psychotic presentations of SCZ, as described in the likely eponymous mid-19th century poem 'Porphyria's Lover' , by Robert Browning 60 , and have been cited as a likely diagnosis for the various psychiatric and metabolic ailments of Vincent van Gogh [61] [62] [63] [64] [65] [66] and King George III (ref. 67 ). Finally, we assessed patterns of expression for the 67 SCZassociated genes throughout development using spatiotemporal transcriptomic data obtained from BrainSpan. We identified four clusters of genes, with expression in four distinct spatiotemporal regions, ranging from early prenatal to strictly postnatal expression. There are plausible hypotheses and genetic evidence for SCZ disease development in adolescence, given the correlation with age of onset, as well as prenatally, supported by genetic overlap with neurodevelopmental disorders [68] [69] [70] and the earlier onset of cognitive impairments [71] [72] [73] [74] . Understanding the temporal expression patterns of SCZ-associated genes can help to elucidate gene development and trajectory and inform research and analysis design. Identification of SCZ-associated genes primarily expressed prenatally is notable given our adult eQTL reference panels and may reflect common eQTL architecture across development, which is known to be partial [75] [76] [77] ; therefore, our results should spur interest in extending transcriptomic imputation data and/or methods to early development 75 . Identification of SCZ-associated genes primarily expressed in adolescence and adulthood is of particular interest for direct analysis of the brain transcriptome in adult psychiatric cases. eQTL data have been recognized for nearly a decade as potentially important for understanding complex genetic variation. Nicolae et al. 1 showed that common variant-common disease associations are strongly enriched for genetic regulation of gene expression. Therefore, integrative approaches combining transcriptomic and genetic association data have great potential. Current transcriptomic imputation association analyses increase power for genetic discovery, with great potential for further development, including leveraging additional data types such as chromatin modifications 78 (for example, methylation or histone modification), imputing different tissues or different exposures (for example, age, smoking, or trauma) and modeling trans/coexpression effects. It remains critical to leverage transcriptomic imputation associations to provide insights into specific disease mechanisms. Here, the accelerated identification of disease-associated genes allows the detection of novel pathways and distinct spatiotemporal patterns of expression in SCZ risk.
URLs. 'CoCo' , an R implementation of GCTA-COJO, https://github. com/theboocock/coco/; Gene2pheno, gene2pheno.org; publicly available whole-blood-derived S-PrediXcan results (as of March 2018), https://github.com/laurahuckins/CMC_DLPFC_prediXcan.
Online content
Any methods, additional references, Nature Research reporting summaries, source data, statements of data availability and associated accession codes are available at https://doi.org/10.1038/ s41588-019-0364-4. . Genes with R cv 2 > 0.01 (~P < 0.05) were included in our final predictor database.
Prediction models were compared across four different regression methods, elastic net (prediXcan), ridge regression (using the TWAS method 16 ), Bayesian sparse linear mixed modeling (BSLMM; TWAS), and linear regression, using the best eQTL for each gene (Supplementary Fig. 1a ). Mean R cv 2 values were significantly higher for elastic net regression (mean R cv 2 = 0.056) than for eQTLbased prediction (mean R cv 2 = 0.025), BSLMM (mean R cv 2 = 0.021) or ridge regression (mean R cv 2 = 0.020). The distribution of R cv 2 values was also significantly higher for elastic net regression than for any other method (Kolmogorov-Smirnov test, P < 2.2 × 10
−16
).
Replication of gene expression prediction models in independent data.
Predictive accuracy of CMC DLPFC models were tested in two independent data sets.
First, we used data from the Religious Orders Study and Memory and Aging Project (ROSMAP 19, 20 ). This study included genotype data and DLPFC RNA-seq data for 451 individuals of European descent (Supplementary Fig. 2b ).
DLPFC GREX was calculated using the CMC DLPFC predictor models. Correlation between RNA-seq expression and CMC DLPFC GREX ('replication R 2 values' or R R 2 ) was used as a measure of predictive accuracy. R R 2 was calculated including correction for ten ancestry components, as follows: R R 2 calculation: ; Supplementary Fig. 3a) . 55.7% of CMC DLPFC genes had R R 2 values > 0.01. Prediction accuracy was also assessed for 11 publicly available GTEx neurological predictor databases, and R R 2 values were used to compare with CMC DLPFC performance. CMC DLPFC models had higher average R R 2 values, more genes with R R 2 > 0.01, and significantly higher overall distributions of R R 2 values than any of the 12 GTEx brain tissue models (KS test, P < 2.2 × 10 −16
; Fig. 1a,b) . To estimate trans-ancestral prediction accuracy, GREX was calculated for 162 African American individuals and 280 European individuals from the NIMH Human Brain Collection Core (HBCC) dataset (Supplementary Fig. 2c ). Predicted gene expression levels were compared to DLPFC expression levels measured using microarray. There was a significant correlation between the European and African American samples for R CV 2 values and R R 2 values (ρ = 0.66, 0.56; Supplementary  Fig. 3b,c) . R R 2 values were higher on average in Europeans, but were significantly correlated between African Americans and Europeans (ρ = 0.78, P < 2.2 × 10 −16 , Pearson test; Supplementary Fig. 3d ).
Extension to summary statistics. Transcriptomic imputation may be applied to summary statistics instead of raw data, in instances where raw data are unavailable. However, this method suffers from slightly reduced accuracy, requires covariance matrices calculated in an ancestrally matched reference population 24 (usually only possible for European cohorts), and precludes testing of endophenotypes within the data, and so should not be applied when raw data are available.
We assessed concordance between CMC DLPFC transcriptomic imputation results using summary statistics (S-PrediXcan 24 ) and raw genotypes (PrediXcan 15 ) using nine European and three Asian PGC-SCZ cohorts 22 for which both data types were available. Cohorts were chosen to encompass a range of case/control ratios, to test previous suggestions that accuracy is reduced in unbalanced cohorts 24 . Covariances for all variants included in the DLPFC predictor models were computed using S-PrediXcan 24 . For all European cohorts, Pearson correlation of log 10 P values and effect sizes was above 0.95. The mean correlation was 0.963 ( Supplementary Fig. 11 ). There was no correlation between total sample size, case/ control ratio, P value or effect size. Seven genes were removed due to discordant P values. For the three Asian cohorts tested, the mean correlation was 0.91 ( Supplementary Fig. 12 ).
Concordance was also tested for the same nine European PGC-SCZ cohorts, across 12 neurological GTEx prediction databases. All correlations were significant (ρ > 0.95, P < 2.2 × 10
−16
). There was a significant correlation between P-value concordance and case/control ratio (ρ = 0.37, P = 7.606 × 10
−15
). 114 genes had discordant P values between the two methods and were excluded from future analyses.
Application to schizophrenia. Dataset collection. We obtained 53 discovery cohorts for this study, including 40,299 SCZ cases and 65,264 controls ( Supplementary Fig. 4 ). Of 53 cohorts, 52 (35,079 cases, 46,441 controls) were obtained through collaboration with the Psychiatric Genomics Consortium and are described in the 2014 PGC SCZ GWAS 22 . The remaining cohort, referred to as CLOZUK2, constitutes the largest single cohort of individuals with SCZ (5,220 cases and 18,823 controls), collected as part of an effort to investigate treatmentresistant SCZ 59 . Of 53 datasets, 50 included individuals of European ancestry, and three datasets included individuals of Asian ancestry (1,836 cases, 3,383 controls). All individuals were ancestrally matched to controls. Information on genotyping, quality control, and other data management issues may be found in the original papers describing these collections 22, 59 . All sample collections complied with ethical regulations. Details regarding ethical compliance and consent procedures may be found in the original manuscripts describing these collections 22, 59 . Access to dosage data was available for 44/52 PGC-SCZ cohorts. The remaining PGC cohorts and the CLOZUK2 cohort provided summary statistics. Three European PGC cohorts were trio-based, rather than case-control.
Additionally, we tested for replication of our CMC DLPFC associations in an independent dataset of 4,133 cases and 24,788 controls obtained through collaboration with the iPSYCH-GEMS SCZ working group (effective sample size 14,169.5; Supplementary Fig. 4b , Supplementary Note).
Transcriptomic imputation and association testing. Transcriptomic imputation was carried out individually for each case-control PGC-SCZ cohort with available dosage data (44/52 cohorts). Predicted gene expression levels were computed using the DLPFC predictors described in this manuscript, as well as for 11 other brain tissues prediction databases created using GTEx tissues (http://gtexportal.org/ home/documentationPage) 15, 21, 79 (Fig. 1c) . Associations between predicted gene expression values and case-control status were calculated using a linear regression test in R. Ten ancestry principal components were included as covariates. Association tests were carried out independently for each cohort, across 12 brain tissues.
For the eight PGC cohorts with no available dosage data, the three PGC trio-based analyses, and the CLOZUK2 cohort, a summary-statistic-based transcriptomic imputation approach was used ('S-PrediXcan 24 '), as described previously.
Meta-analysis. Meta-analysis was carried out across all 53 cohorts using METAL 80 .
Cochran's Q test for heterogeneity was implemented in METAL 80, 81 , and a heterogeneity P-value threshold of P > 1 × 10 −3 applied to results. A conservative significance threshold was applied to these data, correcting for the total number of genes tested across all tissues (121,611 gene-region tests in total). This resulted in a genome-wide significance threshold of 4.1 × 10 −7
. expression throughout development and across brain regions. Clusters were formally identified using a dendrogram cut at height 10 ( Supplementary Fig. 9 ).
In silico replication of SCZ-associated genes in mouse models. We downloaded genotype, knock-out allele information, and phenotyping data for ~10,000 mouse mutant models from five large mouse phenotyping and genotyping projects; Mouse Genome Informatics (MGI 51 ), EuroPhenome 48, 93 , Mouse Genome Project (MGP 48, 49 ), International Mouse Phenotyping Consortium (IMPC 94 ), and Infection and Immunity Immunophenotyping (3I 94 ). Where possible, we also downloaded raw phenotyping data regarding specific assays. In total, we obtained 175,012 phenotypic measurements, across 10,288 mutant mouse models. We searched for any mouse lines with phenotypes related to behavior (natural, observed, stereotypic, or assay induced); cognition or working memory; brain, head, or craniofacial dysmorphology; retinal or eye morphology, and/or vision or visual dysfunction or impairment; ear morphology or hearing dysfunction or impairment; neural tube defects; brain and/or nervous system development; abnormal nociception.
We calculated the rate of phenotypic abnormalities in all mouse lines with reduced expression of genes identified in our prediXcan analysis ('SCZ-associated mouse lines'). We compared these to (1) the 'baseline' rate of phenotypic abnormalities across all 10,288 mouse lines; and (2) the rate of abnormalities in mouse lines associated with other disorders. To do this, we downloaded all publicly available whole-blood-derived S-PrediXcan results (as of March 2018, see URLs). In total, we obtained data for 1,907 genes reaching P < 5 × 10
, across 65 studies.
Effect sizes and direction of effect quoted in this manuscript refer to changes in predicted expression in cases compared to controls, that is, genes with negative effect sizes have decreased predicted expression in cases compared to controls.
Identifying independent associations.
We identified a number of genomic regions which contained multiple gene associations and/or genes associated across multiple tissues. We identified 58 of these regions, excluding the MHC, based on distance between associated genes, and verified them using visual inspection. In order to identify independent genic associations within these regions, we carried out a stepwise forward conditional analysis following 'GCTA-COJO' theory 82 using 'CoCo' (see URLs), an R implementation of GCTA-COJO. CoCo allows the specification of custom correlation matrices by the user (for example, ancestrally specific LD matrices). For each region, we generated a predicted gene expression correlation matrix for all significant genes (p ≤ 1 × 10
), as the root-effective sample size 80 (N eff , equation (2)) weighted average correlation across all cohorts where we had access to dosage data.
Effective sample size, N eff : Forward stepwise conditional analysis of all significant genes was carried out using joint linear regression modeling. First, the top-ranked gene was added to the model, then the next most significant gene in a joint model is added if significant at a given P-value threshold and so on until either all genes are added to the model or no joint statistic reaches the significance threshold. We calculated effect sizes and odds ratios for SCZ-associated genes by adjusting 'CoCo' betas to have unit variance (Table 1 , equation (3)).
GREX beta adjustment:
CoCo where GVAR is the variance of the GREX predictor for each gene.
Gene set analyses. Pathway analyses were carried out using an extension to MAGMA 83 . P values were assigned to genes using the most significant P value achieved by each gene in the meta-analysis. We then carried out a competitive gene set analysis test using these P values, using two gene sets:
1. 159 gene sets with prior hypotheses for involvement in SCZ development, including loss-of-function intolerant genes, CNV-intolerant genes, targets of the fragile-X mental retardation protein, CNS-related gene sets, and 104 behavioral and neurological pathways from the Mouse Genome Informatics database 14, 59, 68, 84 . 2. An agnostic analysis, including ~8,500 gene sets collated from publicly available databases including GO 85, 86 , KEGG 87 , REACTOME 88 , PANTHER 89, 90 , BIOCARTA (MSigDB Collections, 2017), and MGI 51 . Sets were filtered to include only gene sets with at least ten genes.
Significance levels were adjusted across all pathways included in either test using the Benjamini-Hochberg 'FDR' correction in R 26 .
Coexpression of SCZ genes throughout development. We investigated spatiotemporal expression of our associated genes using publicly available developmental transcriptome data, obtained from the BrainSpan consortium 52 . We partitioned these data into biologically relevant spatiotemporal data sets 91 , corresponding to four general brain regions, the frontal cortex, temporal and parietal regions, sensory-motor regions, and subcortical regions 92 ( Fig. 3a) , and eight developmental time points (four prenatal, four postnatal) 91 . First, we tested for correlation of gene expression for all SCZ-associated genes at each spatiotemporal time point. Genes with Pearson correlation coefficients ≥0.8 or ≤−0.8 were considered coexpressed. 100,000 iterations of this analysis were carried out using random gene sets with equivalent expression level distributions to the SCZ-associated genes. For each gene set, a gene coexpression network was created, with edges connecting all coexpressed genes. Networks were assessed using three criteria: first, the number of edges within the network, as a crude measured of connectedness; second, the Watts-Strogatz average path length between nodes, as a global measure of connectedness across all genes in the network 53 ; third, the Watts-Strogatz clustering coefficient, to measure tightness of the clusters within the network 53 . For each spatiotemporal time point, we plotted gene-pair expression correlation (Supplementary Fig. 7 ) and coexpression networks ( Supplementary Fig. 8 ).
For each of the 67 SCZ-associated genes, we calculated average expression at each spatiotemporal point. We then calculated z score of expression specificity using these values and plotted z scores to visually examine patterns of gene
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Describe the software used to analyze the data in this study.
PrediXcan and MetaXcan Python code, publicly available through github: https:// github.com/hakyimlab/PrediXcan GTEX models version 6 were used. Some custom code was used to make PrediXcan compliant with PGC data formats. Code will be made available on request.
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Description of human research participants
Describe the covariate-relevant population characteristics of the human research participants.
We obtained 53 discovery cohorts for this study, including 40,299 SCZ cases and 65,264 controls ( Figure 2 ). 52/53 cohorts (35,079 cases, 46,441 controls) were obtained through collaboration with the Psychiatric Genomics Consortium, and are described in the 2014 PGC Schizophrenia GWAS22. The remaining cohort, referred to as CLOZUK2, constitutes the largest single cohort of individuals with Schizophrenia (5,220 cases and 18,823 controls), collected as part of an effort to investigate treatment-resistant Schizophrenia.
50/53 datasets included individuals of European ancestry, while three datasets include individuals of Asian ancestry (1,836 cases, 3,383 controls). All individuals were ancestrally matched to controls. Information on genotyping, quality control and other data management issues may be found in the original papers describing these collections. Specifically, please see: https://www.nature.com/article-assets/ npg/nature/journal/v511/n7510/extref/nature13595-s1.pdf
